US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eaton Vance Massachusetts Municipal Bond Fund

12.28

0.0000

Volume:- -

Turnover:- -

Market Cap:21.72M

PE:-31.18

High:12.28

Open:12.28

Low:12.28

Close:12.28

52wk High:13.97

52wk Low:11.77

Shares:1.77M

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3939

EPS(LYR):-0.3939

ROE:--

ROA:--

PB:0.86

PE(LYR):-31.18

Loading ...

Overview Company News Filings

Shore Capital Sticks to Their Buy Rating for Mitchells & Butlers (MAB)

Mitchells & Butlers (MAB) Gets a Buy from Shore Capital

Press Release: Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

I-MAB Reports Positive Phase I Results for Givastomig in Gastroesophageal Cancer

I MAB (ADS) trading halted, news pending

Press Release: Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

Leerink Partners Initiates Coverage on I-MAB With Outperform Rating, $9 Price Target

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)

Deutsche Bank Sticks to Their Hold Rating for Mitchells & Butlers (MAB)

Shore Capital Keeps Their Buy Rating on Mitchells & Butlers (MAB)

BTIG Initiates I-MAB at Buy With $7 Price Target

MT Newswires Live

I-MAB Q2 EPADS $(0.07) Up From $(0.11) YoY , Cash And Cash Equivalents, And Short-term Investments Of $165.6M Expected To Provide Cash Runway Into Q4 Of 2028

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MAB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAB\",,,,,undefined,":{"symbol":"MAB","market":"US","secType":"STK","nameCN":"Eaton Vance Massachusetts Municipal Bond Fund","latestPrice":12.28,"timestamp":1575925200000,"preClose":12.28,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":1768514,"eps":-0.3939,"marketStatus":"Delisted","change":0,"latestTime":"12-09 16:00:00 EST","open":12.28,"high":12.28,"low":12.28,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.3939,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":12.28,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAB\",,,,,undefined,":{"symbol":"MAB","floatShares":0,"roa":"--","roe":"--","lyrEps":-0.3939,"shares":1768514,"dividePrice":0,"high":12.28,"amplitude":0,"preClose":12.28,"low":12.28,"week52Low":11.77,"pbRate":"0.86","week52High":13.97,"institutionHeld":0.0082,"latestPrice":12.28,"eps":-0.3939,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.3939,"open":12.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-12-12","symbol":"MAB","amount":0.0533,"name":"Eaton Vance Massachusetts Muni","currency":"USD","type":"dividend","dateTimestamp":1544590800000},{"market":"US","date":"2018-11-21","symbol":"MAB","amount":0.0434,"name":"Eaton Vance Massachusetts Muni","currency":"USD","type":"dividend","dateTimestamp":1542776400000},{"market":"US","date":"2018-10-23","symbol":"MAB","amount":0.0434,"name":"Eaton Vance Massachusetts Muni","currency":"USD","type":"dividend","dateTimestamp":1540267200000},{"market":"US","date":"2018-09-20","symbol":"MAB","amount":0.0434,"name":"Eaton Vance Massachusetts Muni","currency":"USD","type":"dividend","dateTimestamp":1537416000000},{"market":"US","date":"2018-08-23","symbol":"MAB","amount":0.0434,"name":"Eaton Vance Massachusetts Muni","currency":"USD","type":"dividend","dateTimestamp":1534996800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAB\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-20","recordDate":null,"paymentDate":null,"value":0.0492,"currency":"USD"},{"executeDate":"2017-02-16","recordDate":null,"paymentDate":null,"value":0.0492,"currency":"USD"},{"executeDate":"2017-03-22","recordDate":null,"paymentDate":null,"value":0.0467,"currency":"USD"},{"executeDate":"2017-04-19","recordDate":null,"paymentDate":null,"value":0.0467,"currency":"USD"},{"executeDate":"2017-05-22","recordDate":null,"paymentDate":null,"value":0.0434,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603955744","title":"Shore Capital Sticks to Their Buy Rating for Mitchells & Butlers (MAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603955744?lang=en_us&edition=fundamental","pubTime":"2026-01-16 11:15","pubTimestamp":1768533339,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Shore Capital reiterated a Buy rating on Mitchells & Butlers. The company’s shares closed yesterday at p279.00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/shore-capital-sticks-to-their-buy-rating-for-mitchells-butlers-mab-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/shore-capital-sticks-to-their-buy-rating-for-mitchells-butlers-mab-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAB"],"gpt_icon":0},{"id":"2587175909","title":"Mitchells & Butlers (MAB) Gets a Buy from Shore Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2587175909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587175909?lang=en_us&edition=fundamental","pubTime":"2025-11-29 11:25","pubTimestamp":1764386729,"startTime":"0","endTime":"0","summary":"Shore Capital analyst reiterated a Buy rating on Mitchells & Butlers yesterday. The company’s shares closed yesterday at p288.50. The word on The S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mitchells-butlers-mab-gets-a-buy-from-shore-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mitchells-butlers-mab-gets-a-buy-from-shore-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAB"],"gpt_icon":0},{"id":"2581988000","title":"Press Release: Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988000?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518600,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Nov. 7, 2025 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2025.Dr. Schaber continued, \"With approximately $10.5 million in cash at September 30, 2025, we're focused on carefully allocating resources to hit our strategic goals and upcoming milestones. While this cash balance provides sufficient operating runway through 2026, we continue to evaluate all strategic options, including partnership, merger and acquisition, government grants, and potential financing opportunities to advance our late-stage pipeline and the Company.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4022","BK4168","BK4555","BK4604","IDR","MAB","BK4232","R","BK4585","03160","BK4588","BK4099"],"gpt_icon":0},{"id":"2579909915","title":"I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2579909915","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579909915?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:00","pubTimestamp":1761742800,"startTime":"0","endTime":"0","summary":"New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwideStrategy centers on broadening access to global cap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176512/0/en/I-MAB-Nasdaq-IMAB-Transitions-to-NovaBridge-Biosciences-Nasdaq-NBP-with-Trading-Effective-October-30-2025-New-Brand-and-Logo-to-Reflect-Strategic-Transformation-to-a-Global-Biotech.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1803068979.SGD","LU1044875133.USD","BK4526","LU1981816686.USD","LU0149534421.HKD","LU1242518857.USD","LU0106959298.USD","TSYW.SI","LU0821914370.USD","NVIW.SI","LU1316542783.SGD","LU1734074674.USD","PSQ","SQQQ","LU0642271901.SGD","LU2360106780.USD","USJW.SI","QLD","LU0314109678.HKD","IMAB","HEXmain","QID","MAB","PFS","TQQQ","LU0819123356.HKD","IE0009356076.USD","USAW.SI","MNQmain","LU0370786039.SGD","LU1328277881.USD","80388","BK1131","NQmain","LU1993786604.SGD","LU2449936058.SGD","IE00B5949003.HKD","00388","LU0169518387.USD","LU0516422440.USD","IPO","LU0082616367.USD","NBP","LU0043850808.USD","LU1282649141.HKD","LU1807302812.USD","LU0651947912.USD",".IXIC","HKXCY"],"gpt_icon":1},{"id":"2577515347","title":"BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2577515347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577515347?lang=en_us&edition=fundamental","pubTime":"2025-10-24 19:45","pubTimestamp":1761306349,"startTime":"0","endTime":"0","summary":"In a report released today, Justin Zelin from BTIG reiterated a Buy rating on I-MAB, with a price target of $9.00. The company’s shares closed yest...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-i-mab-imab-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-i-mab-imab-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMAB","NBP","MAB"],"gpt_icon":0},{"id":"2577532604","title":"I-MAB Reports Positive Phase I Results for Givastomig in Gastroesophageal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2577532604","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577532604?lang=en_us&edition=fundamental","pubTime":"2025-10-24 05:27","pubTimestamp":1761254873,"startTime":"0","endTime":"0","summary":"I-MAB ( ($IMAB) ) has provided an announcement. On October 23, 2025, I-MAB released updated results from its Phase I monotherapy study of Givastomi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","IMAB","MAB","BK4139","BK4535","BK4526","NBP"],"gpt_icon":0},{"id":"2576773677","title":"I MAB (ADS) trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2576773677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576773677?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:05","pubTimestamp":1760645151,"startTime":"0","endTime":"0","summary":"16:01 EDT I MAB (ADS) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/i-mab-ads-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/i-mab-ads-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAB"],"gpt_icon":0},{"id":"2575379292","title":"Press Release: Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2575379292","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575379292?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:30","pubTimestamp":1760441400,"startTime":"0","endTime":"0","summary":"Providing Strategic Medical Guidance in Advancing HyBryte Clinical Development. PRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the update of its United States  Medical Advisory Board  for cutaneous T-cell lymphoma  to provide medical/clinical strategic guidance to the Company as it advances the Phase 3 clinical development of HyBryte  for the treatment of CTCL, a rare class of non-Hodgkin's lymphoma .Comprised of dermatologic and oncologic thought leaders with extensive experience in CTCL, the MAB has played an important advisory role in the conduct of the ongoing FLASH2 Phase 3, pivotal clinical study and will continue to contribute to the program as we advance development activities including worldwide regulatory interactions with health authorities. With recent retirements, the MAB has been updated t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAB","BK4555","BK4585","TM","EMA","BK4081","BK4604","03160","BK4588","BK4211","BK4099","UBCP"],"gpt_icon":0},{"id":"2575295378","title":"BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575295378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575295378?lang=en_us&edition=fundamental","pubTime":"2025-10-14 17:56","pubTimestamp":1760435760,"startTime":"0","endTime":"0","summary":"BTIG analyst Justin Zelin maintained a Buy rating on I-MAB yesterday and set a price target of $7.00. The company’s shares closed yesterday at $5.7...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-i-mab-imab-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-i-mab-imab-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMAB","MAB"],"gpt_icon":0},{"id":"2572049745","title":"Leerink Partners Initiates Coverage on I-MAB With Outperform Rating, $9 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2572049745","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572049745?lang=en_us&edition=fundamental","pubTime":"2025-10-03 19:31","pubTimestamp":1759491090,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Coverage on I-MAB With Outperform Rating, $9 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMAB","MAB"],"gpt_icon":0},{"id":"2572550925","title":"Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2572550925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572550925?lang=en_us&edition=fundamental","pubTime":"2025-10-03 18:30","pubTimestamp":1759487445,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), I-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-maze-therapeutics-inc-maze-i-mab-imab-and-cidara-therapeutics-cdtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-maze-therapeutics-inc-maze-i-mab-imab-and-cidara-therapeutics-cdtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4505","BK4585","MAZE","BK4137","HCSG","BK4588","MAB","CDTX","BK4535","BK4007","BK4139","LABU","BK4581","XLV","IMAB","BK4526"],"gpt_icon":0},{"id":"2570682864","title":"Deutsche Bank  Sticks to Their Hold Rating for Mitchells & Butlers (MAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570682864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570682864?lang=en_us&edition=fundamental","pubTime":"2025-09-27 18:26","pubTimestamp":1758968768,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tim Barrett from Deutsche Bank maintained a Hold rating on Mitchells & Butlers, with a price target of £3.00. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/deutsche-bank-sticks-to-their-hold-rating-for-mitchells-butlers-mab-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/deutsche-bank-sticks-to-their-hold-rating-for-mitchells-butlers-mab-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DB","MAB"],"gpt_icon":0},{"id":"2570005485","title":"Shore Capital Keeps Their Buy Rating on Mitchells & Butlers (MAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570005485","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570005485?lang=en_us&edition=fundamental","pubTime":"2025-09-26 16:56","pubTimestamp":1758876991,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Shore Capital reiterated a Buy rating on Mitchells & Butlers. The company’s shares opened today at p243.03. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/shore-capital-keeps-their-buy-rating-on-mitchells-butlers-mab-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/shore-capital-keeps-their-buy-rating-on-mitchells-butlers-mab-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAB"],"gpt_icon":0},{"id":"2566691691","title":"BTIG Initiates I-MAB at Buy With $7 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2566691691","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566691691?lang=en_us&edition=fundamental","pubTime":"2025-09-09 19:25","pubTimestamp":1757417148,"startTime":"0","endTime":"0","summary":"I-MAB (IMAB) has an average rating of buy and mean price target of $6.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and rese","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAB","IMAB"],"gpt_icon":0},{"id":"2560170168","title":"I-MAB Q2 EPADS $(0.07) Up From $(0.11) YoY , Cash And Cash Equivalents, And Short-term Investments Of $165.6M Expected To Provide Cash Runway Into Q4 Of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2560170168","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560170168?lang=en_us&edition=fundamental","pubTime":"2025-08-20 19:20","pubTimestamp":1755688856,"startTime":"0","endTime":"0","summary":"I-MAB Q2 EPADS $(0.07) Up From $(0.11) YoY , Cash And Cash Equivalents, And Short-term Investments Of $165.6M Expected To Provide Cash Runway Into Q4 Of 2028","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47230445/i-mab-q2-epads-0-07-up-from-0-11-yoy-cash-and-cash-equivalents-and-short-term-investments-of-165-6m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4505","IMAB","MAB","BK4535","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}